Linde Partners with 3D Medlab in Pioneering Research to Optimize 3D Printing of Complex Structures for Medical Devices

Today Linde announced it has started pioneering research into how atmospheric conditions in the additive manufacturing process can be optimized to produce complex latticed structures for medical devices. In collaboration with 3D Medlab, a leader in additive manufacturing for the medical sector, the joint project is the first of its kind and represents a milestone in the field of orthopedic device development.

Multifaceted, latticed components aim to mimic human body parts and can better assimilate into the patient’s own bone and tissue structure, leading to fewer rejections and quicker healing times. Additive manufacturing can optimize the production of such components ensuring high-quality repeatability of the process and requiring less post-print finishing. However, the atmosphere in the printing chamber needs to be optimal and reproducible.

Atmospheric gases play a fundamental role in the printing process and any impurities that remain in the chamber, even once purged, can have a detrimental effect on the part being manufactured. Additionally, fumes created during the production process can remain on the part, requiring post-production cleaning.

Even extremely small variations in oxygen content can impair the mechanical or chemical properties of metals sensitive to oxygen – such as titanium and aluminum alloys – and can affect the composition of the end product. For the Linde/3D Medlab research trials, the titanium alloy in question is Ti-6AI-4V.

“We are proud to be collaborating with 3D Medlab on this important and forward-looking project,” said Pierre Forêt, Senior Expert Manufacturing, Linde. “As a customer at the forefront of medical device manufacturing, anything less than optimal product outcomes is critically important to avoid, so it is testament to our gases expertise and know-how that we have been selected to partner in this endeavor.”

The atmospheric trials involve a new helium/argon gas mixture created especially by Linde for the project to make the process smoother and cleaner, along with use of Linde’s ADDvance O2 precision, a first-of-a-kind oxygen measuring and analysis technology to ensure the optimal mix of gases within the print chamber. Along with the new gas mixture, ADDvance O2 precision will give 3D Medlab precise, granular control over the oxygen concentration and humidity levels in the print chamber.

“Our experience with Linde shows that they are as committed to the same high standards of precision and excellence in additive manufacturing that we are,” said Gaël Volpi, CEO, 3D Medlab. “Full regulatory compliance is a fundamental cornerstone in our engineering and design process and our customers trust us to ensure all proper measures and controls are in place.”

Linde began its association with 3D Medlab originally through the supply of its ADDvance powder cabinet, designed to retain the quality of valuable, sensitive metal powders used in the additive manufacturing process by protecting them from exposure to ambient air and humidity. While the current collaboration between Linde and 3D Medlab is focused on Ti-6AI-4V lattice structures, future efforts will include the potential of nickel titanium (also known as nitinol) in view of its excellent shape memory and super elasticity, making it an ideal candidate for next generation stents.

SourceLinde

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”